Focus: Lonza is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Basel, Switzerland, serving the pharmaceutical and biotech industries at scale with 10,001-50,000 employees.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Hot — 804 jobs added in 30d
Net +579 (804 new, 225 removed). Aggressive expansion phase.
Lonza is ideal for operations, manufacturing, and quality professionals seeking stable, high-volume manufacturing roles in a well-established CDMO; less attractive for those seeking discovery-driven innovation or rapid pipeline catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lonza
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lonza's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ImmuneOncia signs manufacturing agreement with Lonza for Danburstotug - Drug Discovery News
ImmuneOncia signs manufacturing agreement with Lonza for Danburstotug Drug Discovery News
Lonza Group AG stock: What investors should know about its biotech edge now - AD HOC NEWS
Lonza Group AG stock: What investors should know about its biotech edge now AD HOC NEWS
Torqur, Lonza Partner to Advance Oncology Drug Candidate - Contract Pharma
Torqur, Lonza Partner to Advance Oncology Drug Candidate Contract Pharma
Torqur AG strengthens bimiralisib development through Lonza partnership - Drug Discovery News
Torqur AG strengthens bimiralisib development through Lonza partnership Drug Discovery News
ImmuneOncia, Lonza Sign Manufacturing Pact for Late‑Stage Antibody Program - Contract Pharma
ImmuneOncia, Lonza Sign Manufacturing Pact for Late‑Stage Antibody Program Contract Pharma
Lonza Group AG Stock: A Key Player in Biopharma Manufacturing for North American Investors - AD HOC NEWS
Lonza Group AG Stock: A Key Player in Biopharma Manufacturing for North American Investors AD HOC NEWS
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Sequential digestions enable identification and quantification of rapid aspartic acid isomerization in the CDR of a monoclonal antibody light chain.
Disulfide bond reduction of antibodies during clarification: A bench-scale assay and a mitigation tool.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo